Neurotoxicity of an Hepatitis B Virus (HBV) Transcript Inhibitor in 13-Week Rat and Monkey Studies. (3rd February 2022)

• Record Type: Journal Article
• Authors: Lake, April D; Holsapple, Kevin; McDonnell, Tanya; Arezzo, Joseph C; Ramirez, Ricardo; Gamelin, Lindsay; Yu, Mei; Glatt, Dylan; Dick, Ryan; Xie, Xiaodong; Choy, Regina; Cheng, Guofeng; Tay, Chin H; Chester, Anne; Kato, Darryl; Burns-Naas, Leigh Ann
• Is Part Of: Toxicological sciences. Volume 186:Number 2(2022)
• Page Start: 298
• Page End: 308
• Publication Date: 2022-02-03
• Subjects: neurotoxicity -- peripheral neuropathy -- benchmark dose -- HBV; Toxicology -- Periodicals; Toxicology -- Periodicals; Toxicology; Periodicals; 615.9
• DOI: 10.1093/toxsci/kfac009
• Languages: English
• ISSNs: 1096-6080

Abstract

Abstract: The nonclinical safety profile of GS-8873, a hepatitis B virus RNA transcript inhibitor was evaluated in rat and monkey 13-week toxicity studies with 8-week recovery phases. Vehicle or GS-8873 was dosed orally for 13 weeks at 2, 6, 20, and 60 mg/kg/day to Wistar Han rats and at 0.5, 1.5, 3, and 6 mg/kg/day to cynomolgus monkeys. In vitro and in vivo screening results from an analog discovered prior to GS-8873 informed the 13-week toxicology study designs. Neuroelectrophysiology and neurobehavioral evaluations were included at weeks 4 and 13 of the dosing and recovery phases for GS-8873. No adverse neurobehavioral effects were observed. Significant nerve conduction velocity (NCV) decreases and latency increases occurred at the high doses after 4 weeks of dosing. By week 13, dose-responsive NCV reductions and latency increases worsened across all dose groups compared with controls. Some reversal occurred 8 weeks after the last dose administered, but not to vehicle control levels. A minimal, axonal degeneration was observed in rat spinal and peripheral nerves across dose groups compared with controls. No monkey nervous system microscopic findings were observed. No-observed-adverse-effect-levels could not be determined for either species due to the neuroelectrophysiology findings and development was halted in the interest of safety. A retrospective risk assessment approach utilizing benchmark dose (BMD) modeling contributed 13-week NCV BMDL estimates (lower limits of the 95% confidence interval) in lieu of no-observed-adverse-effect-levels. The best-fitted models extrapolated NCV BMDLs for the rat caudal and monkey sural nerve at 0.3 and 0.1 mg/kg/day, respectively.